Aleve Warning Gives Pfizer Some Relief, But Is New Headache For FDA

Data from a National Institutes of Health study on Alzheimer's disease prevention showing a cardiovascular safety signal for naproxen present a new challenge for FDA in regulating COX-2 inhibitors